Positive surgical margins after radical prostatectomy lead to an increased risk of progression and reduced disease free survival. Earlier detection of prostate cancer, appropriate patient selection and improved operative techniques can reduce the incidence of positive margins, though the risk can not be eliminated as preoperative staging techniques are not sufficiently sensitive. Nerve sparing and bladder neck sparing do not adversely affect margin status in appropriately selected men. Once positive margins have been diagnosed the optimal management and the timing of treatment remains controversial. Adjuvant radiotherapy or salvage radiotherapy in men with a low PSA may improve local control and PSA free survival in some individuals, a survival benefit has not yet been established.
Introduction
Carcinoma of the prostate is now the commonest malignancy amongst men in most developed countries, and the second most frequent cause of cancer death. 1 Increasing public awareness of the disease has led to a growing number of men being diagnosed with clinically localized prostate cancer on the basis of an elevated prostate specific antigen (PSA) level. Unfortunately, even with the most sophisticated pre-operative staging techniques, an average of 28% of those undergoing radical prostatectomy are found to have positive surgical margins, although the latter series have a lower margin positive rate. 2, 3 Furthermore, once positive margins have been established, the optimum treatment remains controversial.
A positive surgical margin is defined as the presence of tumour at the inked surface of the resected specimen 4 -7 and as such implies incomplete excision of malignant tissue. 4, 8 Where even scant benign tissue separates tumour from the inked surface this should be classified as a negative margin as close margins probably have no impact on patient outcome. 14 Sites designated with margin status are: the apex, which includes the urethral limit, the base, which includes the bladder neck margin, the vasal and the circumferential -anterior, lateral, rectal or posterior surface. 9 -12 Stamey subdivided positive surgical margins into two groups. In the first group the cancer is cut through when it is outside the prostate boundaries into the fat, having penetrated the capsule -a positive extraprostatic limit ( Figure 1c ). In the second group the cancer is cut through inside the glandular area of the prostate due to inadvertent surgical excision of the periprostatic fascia and prostate capsule, which are missing from the histological specimen -a positive intraprostatic limit 9 (Figure 1b ). The first group may be further subdivided into focal, where limited tumour reaches the inked limit in one or two sites, or extensive, where multiple positive margins are present at different sites in the prostate. 13, 14 Epstein et al demonstrated significantly different progression rates between those with negative ( Figure 1a ) compared with equivocal (intraprostatic), focal and extensive extraprostatic surgical margins. However, the subclassification of positive margins has not been standardized. 15 
Positive margins and PSA relapse
The presence of a positive extraprostatic margin suggests inadequate cancer clearance. 4, 8 Patients are at significant risk of biochemical relapse, 50 -60% at 5 y, and subsequent clinical relapse, although by no means every patient will suffer eventual disease recurrence. 4,14,16 -18 Most investigators consider positive surgical margins independent predictors of disease recurrence after radical prostatectomy. 16 Epstein et al, from Johns Hopkins Hospital, reported 79% of men with negative margins were progression-free over a 10 y period compared with 55% of those with positive margins (P < 0.00001). 16 The Johns Hopkins group subsequently demonstrated the effect of Gleason grade on outcome in men with positive margins. They reported positive surgical margins had no impact on 10 y probability of biochemical recurrence in men with Gleason score less than 7. However, men who had a Gleason score of 7 and positive surgical margins did significantly worse than those with extracapsular extension and negative margins. 19 Grossfeld et al calculated that after adjusting for PSA, pathological tumour stage and Gleason grade, patients with positive margins were 2.6 times more likely to have disease recurrence than those with negative margins. 20 Figure 1 (a) High power of radical prostatectomy wholemount section demonstrating organ-confined prostate cancer (EPT, extraprostatic tissue; E, edge of prostate; CAP, prostate cancer). (b) High power of radical prostatectomy wholemount section demonstrating an intraprostatic positive surgical margin (CAP, prostate cancer; IM, inked margin). (c) High power of radical prostatectomy wholemount section demonstrating extraprostatic carcinoma with a positive surgical margin (EPT, extraprostatic tissue; E, edge of prostate; CAP, prostate cancer).
Furthermore, patients with positive margins were significantly more likely to receive adjuvant or nonadjuvant secondary treatment (P ¼ 0.0001). 20 Stamey, however, contested these findings, stating that margin status is not an independent predictor of failure after radical prostatectomy when adjusting for the percentage of Gleason 4 and 5 cancers, tumour volume and lymph node status. 21 Cheng and co-workers examined the correlation between margin status and PSA relapse in a series of 377 patients from the Mayo Clinic. 18 Their overall margin positivity rate was 29% -19% of patients with positive margins without extracapsular disease (intraprostatic), 14% with extracapsular extension with negative margins and 10% with both extracapsular extension and positive margins. Men with organ-confined disease and negative margins had a 90% 5 y progression-free survival. In the cohort with positive margins the 5 y progression-free survival was 78% for those without extracapsular extension and 55% for those with extracapsular extension. 18 Other authors have shown intraprostatic positive margins have little or no effect on outcome, at least in the medium term. 4, 13 Ohori et al reported 100% of men with intraprostatic positive margins were free from tumour recurrence after 5 y compared with 42% with positive margins and extracapsular extension. 4 Nevertheless inadvertent incision into the prostate may potentially leave either benign or malignant tissue behind. Benign tissue is capable of both PSA secretion and eventual malignant transformation.
Factors such as the location, extent and number of positive margins may have an impact on disease recurrence. 22 Blute et al reported that the site of positive margins was a significant predictor of progression. 10 Patients with pT2N0 disease who had a single margin at either the apex/ urethra (the most common) or anterior/posterior prostate or multiple positive margins in these sites had only slightly decreased PSA-free rates compared with patients with negative margins at 5 y (79, 78 and 82% compared with 86% with negative margins). However, patients in whom the prostate base limit was positive had significantly lower clinical or PSA failure free rates -56% at 5 y. The risk of PSA progression was 1.68 times higher in men with positive margins after matching for Gleason score, pre-operative PSA and DNA ploidy in this series. 10 Positive vasal margins are also associated with a poor prognosis. In a series of 105 men undergoing radical prostatectomy, seven (6.7%) cases had vas deferens involvement; in these patients there was a significant correlation with seminal vesicle involvement, extracapsular extension, extensive carcinoma, Gleason score 7 -10 and positive bladder neck margins. All five men with followup developed disease recurrence.
Several groups have highlighted the prognostic difference between a focal compared with an extensive positive margin. 13, 14, 16 Epstein et al reported that focal margins were associated with recurrence in 40% and extensive margins had a 65% risk of progression after 5 y followup. 14 So the site, number and extent of positive surgical margins all provide valuable prognostic information.
Several explanations are given for why a positive margin is not always associated with tumour recurrence. The surgery results in ischaemia and fibrosis, both of which may destroy small areas of residual carcinoma as the malignant tissue is unable to survive in its new environment. Alternatively, it may be a result of the desmoplastic response. This is where the extraprostatic prostate cancer cells are more adherent to the prostate than the surrounding adipose tissue. When the prostate is lifted away from the surrounding tissue the malignant cells adhere to the specimen. 24 Finally the process required to prepare the specimen for histological examination may result in inadvertent damage leading to the false impression of positive surgical margins. 8 The histological method used to assess radical prostatectomy specimens varies and this may account, in part, for the variation in reported margin status. Coronal sections are taken serially at 2 -6 mm. 12,25 -28 Hall et al demonstrated that sections taken at 4 -6 mm intervals missed 12% of positive margins compared with 2 -3 mm sections. 26 The apex may be examined by two different techniques. The distal 1.5 cm of the prostate is amputated and tissue is sectioned in a sagittal plane, with the urethra at the centre -the cone technique 26, 29 (Figure 2) . Alternatively a 'thin shave' transverse section is taken of the apex around the urethra. This tissue block is sectioned from its inferior aspect and examined. The cone technique allows examination of the prostate at its most distal limit, although only 5 mm for every 3 -5 mm section of the distal margin are examined histologically. 14 The shave technique on the other hand is simpler and less time-consuming to perform and the entire surface area of the distal margin is examined. 14 However, with the latter technique there is at least a theoretical risk of over diagnosing positive apical margins as the inked surface is firstly 'roughed down' and so the section taken for microscopic examination is several microns within the prostate.
The definition of a positive apical margin is variable. Epstein, using the shave technique, classified an apical margin as positive if it (1) showed skeletal muscle without benign prostate glands and contained tumour, (2) contained benign glands and any amount of tumour of high grade, or (3) contained benign glands and extensive tumour of any grade. 14 Where there are benign glands and a small focus of low-grade tumour the margin is classified as equivocal and margins are designated negative where no tumour is seen. 14 Stamey describes apical margins in the same way as margins elsewhere in the prostate -margin negative, margin positive with (CPþ) or without (CP7) capsular penetration. 9 Van den Ouden et al defines an apical limit as positive if it is in the distal 5 mm of the prostate. 17 Comparative data are not yet established on PSA relapse in patients with isolated positive apical margins when these differing definitions and techniques are employed.
Avoiding positive margins
Undoubtedly the best way to minimize the risk of positive surgical margins is by careful and appropriate patient selection aided by meticulous surgical technique.
Case selection
Case selection involves correctly identifying those patients most likely to benefit from the treatment. This is of paramount importance in men considered for radical prostatectomy, particularly in terms of reducing the incidence of positive surgical margins. Although there is no absolute means of identifying those individuals with preexisting microscopic invasion of extraprostatic tissue, methods are now available to establish those at highest risk. The most useful of these are the three components incorporated in the tables devised by Partin, namely the clinical stage, the PSA and the Gleason score from the preoperative prostate biopsy. 30 High clinical stage, high pre-operative PSA, high Gleason grade as well as large tumour volume and multiple positive biopsies all increase the risk of positive surgical margins. 5,31 -34 Figure 2 The cone technique for assessing margin status at the apex of the prostate.
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Whilst clinical staging using digital rectal examination is inaccurate at assessing pathological stage, 33 it is a useful predictor of positive margins. In a recent review positive surgical margin rates were: 5% for T1a, 22% for T1b, 23% for T1c, 17% for T2a, 36% for T2b, 27% for T2c and 40% for T3a clinical stage. 23 Depending on the tumour site, clinical stage indirectly reflects tumour volume. Gomez et al showed patients with negative margins had a mean tumour volume of 4.8 ml compared with 12.3 ml in those with positive margins. 6 As tumour size is difficult to assess preoperatively, attempts have been made to compare 35 PSA is also a useful predictor of the risk of positive margins. As the PSA rises the risk increases; the mean PSA for a patient with positive margins is between 16.8 -29.0 ng/ml, whereas for men with negative margins it is 9.27 -16.6 ng/ml. 5, 17 Watson et al 7 compared Gleason sum at biopsy with margin status; they found that, of men who had a Gleason score 7 or greater, 43% had positive margins compared with 30% of men with a Gleason score of less than 7. Although a higher Gleason score increases the risk of positive margins, Ohori et al emphasized the need to combine the Gleason score with the PSA and DRE. This combination identified 60% of poorly differentiated tumours of which 81% were organ-confined. 36 Newer techniques are evolving in an attempt to augment or improve on the 'classical three' pre-operative predictors (biopsy Gleason grade, clinical stage and preoperative PSA score). DNA ploidy has been reported as an independent predictor of outcome after radical prostatectomy, 18,37 -39 although it has not been adequately assessed for use in predicting margin status.
Race is an independent predictor of positive surgical margins 40 and disease-free survival in patients with positive surgical margins. 41 In patients matched for pathological stage, Gleason grade and tumour volume, African-American men were found to have a higher incidence of positive margins compared with white Americans (48 vs 33%, respectively, P ¼ 0.001). 41 Furthermore, African-American men had a higher incidence of positive margins at the bladder base; however in this study, the location of the positive margin did not have an effect on the disease-free survival.
Preoperative imaging. The ability of imaging modalities to correctly stage prostate cancer remains limited, even in the best hands using state-of-the-art equipment. Extracapsular extension is often microscopic and current techniques are not of sufficient resolution to detect small breaches in the capsule. The apex of the prostate is the most frequent site for a positive margin but, as the capsule is ill-defined in this region, 26 it is difficult to distinguish extracapsular from organ-confined tumour. Clearly intraprostatic positive margins are not visualized pre-operatively. Where macroscopic tumour extension is present, endorectal magnetic resonance imaging (eMRI) is the most sensitive and specific technique available; nevertheless there is still a high rate of false positives as well as considerable inter-observer variability. Cornud et al reported eMRI to have a sensitivity of 33% and a specificity of 100% at detecting extracapsular disease, excluding intraprostatic margins. They concluded eMRI is only accurate in a minority of highly selected high risk hypervascular tumours. 42 43 Other modalities including transrectal ultrasound (TRUS), pelvic CT and body coil MRI are not sufficiently accurate to detect extracapsular extension. TRUS is no better than DRE in predicting extracapsular extension in prospective multicentre studies. 44 CT has a reported sensitivity of between 55 and 75% 45, 46 and body coil MRI between 20 and 70% at detecting extracapsular disease. 46, 47 Positron emission tomography (PET), a noninvasive imaging modality, has been investigated for its use in staging prostate cancer. It relies on the increased uptake in tumours of a radiolabelled choline analogue. This technique is still under evaluation, however it is likely only to be of benefit in the staging of prostate cancer that has metastasized as the false positive rate for extracapsular disease is unacceptably high. 48 -50 In practice radiological evidence of extracapsular disease is usually sort only in those men with a high risk -those with a PSA > 20 ng/ ml or with a Gleason score of 8 or more.
Surgical technique
There are three approaches to radical prostatectomyretropubic, perineal and laparoscopic. The incidence of positive surgical margins is very similar for each technique but the location of the margins is dependent upon the approach. 23, 51, 52 The apex is the most common site for positive margins in the retropubic and laparoscopic approaches, whilst the anterior prostate is the most common site when the perineal approach is employed. 7,8,23,51 -54 Table 1 shows the incidence and site of positive margins.
The majority of radical prostatectomy procedures are performed via the retropubic approach in the 'anatomic' manner originally described and subsequently adapted by Walsh. 55 Others have made further modifications such as preserving the bladder neck; proponents argue that this manoeuvre results in an earlier restoration of continence and a lower risk of bladder neck stricture. 56 -59 Unfortunately the scope for making the operation more 'radical' is not all that great, as important structures, such as the distal sphincter, limit the dissection. However, there are a number of ways in which the chance of positive surgical margins can be minimized without compromising the important aim of maintaining urinary continence.
The apex of the prostate. As stated, the most common location of a positive surgical margin is at the apex of the prostate. 7, 8, 10, 54 This is because there is only scant periprostatic tissue at this point and the fibromuscular 'capsule' found elsewhere is absent at the apex. What is more, as prostate cancer has a tendency to invade perineural spaces the short inferior neurovascular pedicle at the apex renders extraprostatic extension more common. 9 Particular care is required not to excise excess 'normal' tissue in this region because of the proximity of the sphincter mechanism and the neurovascular bundles. Potency or continence may occasionally have to be sacrificed in order to obtain the primary objective of cancer cure.
In order to limit positive apical margins while preserving the neurovascular bundle and sphincter mechanism, it is firstly important to mobilize a sufficient length of membranous urethra to enable visualization of the most distal anterior part of the prostate. This is best achieved by ensuring adequate division of the puboprostatic ligaments and the fibromuscular bands anterior to the urethra and tethered to the apex of the prostate. 60 Usually the urethra enters the prostate slightly anterior and proximal to the apex in the 'prostatic notch'. The more distal apex is hidden by the urethra in the retropubic approach. When the urethra is divided in this notch, proximal to the apex, there is a risk of incising into the concealed posterior prostate tissue when dividing the posterior urethra. 60 To prevent this the urethra should be transected at a point distal to the anterior apical tissue. Once this has been accomplished the rectourethralis muscle needs to be divided completely without damaging the rectum. Failure to do this risks violation of the prostate capsule posteriorly. Once the rectourethralis has been divided, the prostate may be bluntly dissected away from the rectum ensuring Denonvillier's fascia remains intact. 60 If retrograde dissection proves difficult or the capsule is breached, an antegrade approach should be considered. 61 The neurovascular bundles. A decision has to be made, based upon the preoperative investigations and pre-existing erectile function, whether or not to spare either or both neurovascular bundles in an attempt to preserve potency. The neurovascular bundles lie outside the capsule and fascia of the prostate; cancer control is therefore not compromised by preserving the bundles, provided the tumour is organs confined. 62 Pound et al 63 reported on a series of 1623 men who underwent radical prostatectomy at Johns Hopkins Hospital. They compared the actuarial recurrence-free probabilities according to tumour stage and margin status in men potent and impotent post-operatively. The groups were similar for age, Gleason grade and stage. With all stages there was no difference in actuarial recurrence-free probability between the potent and impotent men.
The commonest site of capsular penetration is in the region of the neurovascular bundles, posterolateral to the prostate. 64 Moreover, Catalona and Bigg 3 reported that all men who had extracapsular extension in the region of the neurovascular bundles also had positive surgical margins. This has led some to excise the neurovascular bundle on the side of the prostate with the palpable nodule or positive biopsies. This may not suffice as 80% of men with a palpable nodule have bilateral tumour involvement. 65 However, the contralateral tumour burden is usually, but not invariably, less, and in appropriately selected patients nerve sparing can be performed without compromising margin status. 17, 34, 66 A patient should generally fulfil certain criteria before a nerve-sparing technique is utilized:
1. The prostate biopsies should be positive on one side only and ideally only one or two out of six cores should contain tumour. Daniels et al 67 demonstrated that bilateral positive cores correlate with large tumours and an increased probability of capsular penetration and positive surgical margins. 2. The patient should have T1, T2a or T2b clinical stage disease. T1a and T1b are the most suitable for nervesparing surgery as they rarely invade the neurovascular bundles. 68 In T1c prostate cancer Soloway recommends excising the neurovascular bundle on the side of the positive biopsies. 23 Daniels reported on men with T2a and T2b prostate cancer, in whom the contralateral biopsies were cancer-free, had low-volume, localized disease and had a low risk of positive surgical margins with contralateral nerve-sparing. 67 3. The patient should have normal erectile function before surgery and should express a wish to stay potent post-operatively.
Other factors to take into consideration before embarking on nerve-sparing radical prostatectomy include the preoperative PSA, the Gleason score and the site of the tumour. The PSA and Gleason are independent predictors of margin status as outlined above. Tumours situated in the apex are more likely to spread into the perineural spaces as a result of the short length of the inferior pedicle. 9, 69 Preserving the neurovascular bundles in men with apical tumours may increase the risk of positive margins. Consequently, Stamey et al 9 suggested wide excision of all tissues proximal to the membranous urethra to the levator muscles, including the neurovascular bundles and periprostatic fascia, in men with apical lesions. Several studies have shown no statistically significant difference between nerve-sparing and non-nerve-sparing in terms of margins in appropriately selected patients. 34, 66 Overall, nerve-sparing procedures are associated with a 7 -46% positive margin rate compared with 13 -46% for the non-nerve sparing technique. 9, 17, 34, 61, 67, 70, 71 However, in men with induration in or around the lateral pedicle, wide excision of the neurovascular bundle on that side does seem to improve the chances of negative surgical margins and decrease the risk of disease recurrence; 72 although using this criterion 30% of patients will have their neurovascular bundles excised unnecessarily as the cancer is organ-confined. 73 There is no significant effect on potency in men under 50 y old when one neurovascular bundle is excised, however with advancing age sexual function is better in men in whom both bundles are preserved. 74 In general, decisions about whether or not to spare the neurovascular bundles on each side should be made on the basis of the criteria listed above, rather than on the basis of more subjective operative findings.
The bladder neck. Bladder neck sparing was developed in an attempt to reduce the risk of anastomotic stricture and accelerate the return of urinary continence, while maintaining the surgical objective of cancer clearance. 75 Positive margins at the location of the bladder neck are reported in up to 25% of cases when all bladder neck dissection techniques are included. 76 Bladder neck positive margins may be iatrogenic; where there is extracapsular disease and a positive surgical margin there are, almost invariably, positive margins elsewhere. In fact solitary positive bladder neck margins were found in only 1% of specimens in one study. 75 These authors concluded that bladder neck preservation did not compromise surgical outcome and that more extensive resection at the bladder neck would not have been curative. This is consistent with other reports that correlate genuine positive bladder neck margins with poorer prognosis disease -large tumour volume, 6 seminal vesicle invasion 9 and lymph node involvement. 57 As positive bladder neck margins when associated with extracapsular disease coexist with poor prognosis disease, it is unlikely the bladder neck margin affects the overall outcome. What is more, several authors have demonstrated an earlier return to urinary continence 56, 58 and reduced incidence of bladder neck contracture. 57, 75 Other authors have confirmed there is no negative impact on margin status following bladder neck preserving surgery but they have failed to show any significant improvement on return of urinary continence 57 or bladder neck contracture. 59 
Neoadjuvant androgen deprivation
Neoadjuvant androgen deprivation has been shown to reduce the incidence of positive surgical margins and extracapsular disease in a number of studies. 77 -81 This may be because the whole prostate shrinks, allowing wider resection margins, down-staging of the tumour itself or because of difficulties with accurate pathological assessment after hormonal treatment. 23 Either way, there is no evidence from long-term prospective randomized trials that neoadjuvant androgen deprivation has any effect on biochemical relapse 82, 83 or survival. 84 Furthermore, difficulties may arise in giving the prostate specimen an accurate Gleason grade as androgen withdrawal affects the glandular architecture, so important prognostic information may be lost. Given the current data the routine use of neoadjuvant androgen deprivation before radical prostatectomy is unjustified. 84 
Adjuvant treatment options for patients with positive surgical margins
The aim of adjuvant therapy after radical prostatectomy in patients with positive surgical margins is to prevent or delay PSA and subsequent clinical relapse and to prolong survival. However, there is currently no consensus on what, if any, and when such treatment should be offered to these patients. 117 Treatment options have included adjuvant external beam radiotherapy (EBRT), adjuvant androgen deprivation and surveillance with delayed EBRT or androgen ablation at the time of recurrence. 23 Adjuvant radiotherapy is used in an attempt to delay local recurrence or cure residual local disease; adjuvant androgen ablation is primarily used to delay progression of systemic disease. As there is no standard regime, trials set up to elucidate the effects of adjuvant therapy are difficult to compare or to subject to meta-analysis. Furthermore, the effect of the lead-time bias complicates survival comparisons between those treated with adjuvant vs salvage EBRT. Despite these difficulties in interpreting the data, freedom from biochemical recurrence after adjuvant or salvage EBRT is quoted as 20 -100%. 85 Adjuvant radiotherapy. Potential indications for adjuvant radiotherapy include detectable postoperative PSA, 86, 87 high Gleason score, 88 extracapsular disease, 88 seminal vesicle invasion, 86, 89 lymph node involvement 86, 88, 89 and positive surgical margins. 13,89 -91 Of these, positive surgical margins are usually associated with the smallest amount of residual disease and potentially the highest chance of success following adjuvant radiotherapy. 92 There is no data yet available from randomized controlled trials to compare the efficacy of adjuvant EBRT for patients with positive surgical margins. Several non-randomized, retrospective studies have suggested improved local control and prolonged PSA progression-free periods, but no overall survival benefit. 92 -96 Leibovitch et al 93 retrospectively matched two groups of patients with pT2 disease and a positive surgical margin at one site. They found that 88% of men who had adjuvant radiotherapy after radical prostatectomy were free of biochemical and clinical relapse over 5 y compared with 59% of those who had surgery but no adjuvant therapy. Their conclusion was that adjuvant radiotherapy improved clinical disease free survival. However, this and other trials failed to show enhanced metastasis-free rates 92, 97, 98 or an overall survival benefit over the period of the study. 92,97 -100 Salvage radiotherapy. By definition, giving adjuvant treatment to all cases of positive surgical margins will result in some patients receiving radiotherapy, with its potential The American Society of Therapeutic Radiology and Oncology Consensus Panel examined the use of salvage EBRT in patients with PSA relapse after radical prostatectomy. They recommended a dose of at least 64 Gy (or slightly higher if the dose is fractionated) given when the PSA level is less than 1.5 ng/ml. 101 Nudell et al 102 reported a cohort of 105 men treated with either adjuvant or salvage EBRT. They defined disease-free as the achievement and maintenance of a PSA of > 0.2 ng/ml, giving a 5 y overall disease-free survival of 43%. Outcomes were equivalent for the adjuvant and salvage EBRT groups where therapeutic irradiation was administered when the serum PSA was low ( < 1.0 ng/ml).
Patients who receive radiotherapy after surgery fare better if the PSA falls to an undetectable level than those with a persistently detectable PSA (66% at 40 months compared with 20% at 12 months, respectively). 86 What is more, men in whom the PSA rises more than 1 y after surgery and patients who have a low-to moderate-grade tumour have a better response to salvage EBRT. 86, 103 Peschel et al 95 reporting on a series of 52 men who had either adjuvant or salvage EBRT, found the pre-operative PSA, the pre-radiation and seminal vesicle involvement were significant risk factors for biochemical recurrence following post-operative radiotherapy. Using univariate analysis, they suggested a pre-radiotherapy PSA cut-off value of 0.3 ng/ml was useful in predicting disease recurrence in men undergoing salvage EBRT.
Not all patients with positive margins coupled with other adverse prognostic indicators after radical prostatectomy should be considered for radiotherapy. Cadeddu et al 104 found that, at 2 y after salvage radiation treatment, no patients with Gleason score 8 or more, seminal vesicle invasion, lymph node metastases or biochemical recurrence within one year of surgery, were PSA-free. Data is not yet available, however these patients may gain some disease-free advantage by receiving either adjuvant hormonal monotherapy or adjuvant hormonal therapy with EBRT.
Early reports indicated a significant incidence of postradiotherapy complications -chronic radiation proctitis and/or cystitis in 27% of patients and 5% of men requiring a colostomy and 5% a urinary diversion. 99 However, with newer conformal and intensity modulated radiotherapy techniques the incidence of such complications is far lower. 101 Importantly there is no significant effect on urinary continence 105, 106 or potency 107 following the administration of at leastn 45 -54 Gy of adjuvant radiotherapy.
Adjuvant androgen deprivation. In another hormone sensitive cancer, breast cancer, adjuvant therapy has had a highly significant effect on both tumour recurrence and cancer-related mortality. 108 This approach provides a rationale for the use of adjuvant androgen ablation therapy in patients following radical prostatectomy with positive surgical margins or in whom the serum PSA does not become undetectable. 109 Various adjuvant hormonal treatment options are available, including luteinizing hormone releasing hormone (LHRH) analogue monotherapy, maximum androgen blockade, androgen antagonists, 5-alpha-reductase inhibitors and bilateral orchidectomy. To date no survival benefit has been shown from hormonal deprivation for men with positive margins without lymph node metastases. 109, 110 Furthermore, initiating hormone therapy may result in short and long-term side-effects including gynaecomastia, breast pain and osteoporosis. 111 Results from several trials have shown a significant improvement in disease-free surviva, using hormonal deprivation as adjunctive treatment after radical prostatectomy in selected men. In a prospective randomized study Prayer-Galetti et al 112 observed a 25% improvement in disease-free survival after radical prostatectomy in patients with 'C stage' prostate cancer who received the LHRH analogue goserelin compared with the no-adjuvant-treatment control group. Messing et al 110 reported improved overall survival and reduced risk of recurrence in node-positive patients treated with goserelin/orchidectomy rather than observation after radical prostatectomy. The bicalutamide early prostate cancer programme is currently underway to assess the effect of bicalutamide either as immediate or as adjunctive hormonal therapy in men who have undergone radical prostatectomy or EBRT with curative intent. Following a median follow-up period of 2.6 y the risk of disease progression was 13.9% in the placebo arm and 7.3% in the treated group. 113 The results from the sub-group of patients with positive margins have not yet been published. Moreover the survival data will not be available for some time as the median actuarial time after surgery from PSA elevation to the development of metastases is 8 y and to death a further 5 y. 114 Combined androgen deprivation and adjuvant radiotherapy. The EORTC and RTOG randomised prospective trials both demonstrated improved overall survival, freedom from local recurrence and freedom from distant metastases for patients with high-grade or clinically advanced disease treated with androgen deprivation and primary radiotherapy. 105, 115 Yet data on the use of combination therapy in patients with suspected or proven residual disease after radical prostatectomy is scant.
Eulau et al 116 examined men who received androgen ablation two months before, and continuing for a mean of 6 months during and after 60 -70 Gy of adjuvant radiotherapy compared with those receiving adjuvant EBRT alone. The mean follow-up time was 3.1 y for those who had androgen suppression and 4.6 y for those who received radiotherapy alone. Fifty-six percent of the study group had no biochemical recurrence compared with 27% in the control group and 100% vs 70% had no evidence of clinical recurrence, respectively. Positive margins were not a significant risk factor for biochemical recurrence after adjuvant treatment in either group. The follow-up period in this study was short and the duration of androgen withdrawal not standardized.
Several authors have postulated that adjuvant radiotherapy alone may fail to provide a survival benefit because of undetectable micrometastases present at the time of radiotherapy. 99, 117 Anti-androgens induce apoptosis in hormone sensitive prostate cancer cells irres-pective of their location. It is not surprising, therefore, that the risk of biochemical relapse is reduced, at least in the short-term, with androgen deprivation. Whether there is any survival advantage, as seen when androgen ablation is used in conjunction with primary radiotherapy in poor prognosis disease, remains to be seen from ongoing randomized trials.
Conclusions
A positive surgical margin is associated with increased risk of disease progression and decreased disease-specific survival. Appropriate patient selection is essential to reduce the risk of positive surgical margins, utilizing the pre-operative PSA, biopsy Gleason score and findings on DRE together with, in selected cases, endorectal MRI. African-American men with clinically localized prostate cancer have a higher incidence of positive surgical margins and poorer disease-free survival than their white compatriots.
While intraprostatic positive margins may not lead to biochemical or clinical recurrence in the medium term, the patient may develop recurrence in the long term, as benign tissue remaining is capable of malignant transformation, and the patient has the anxiety associated with a detectable PSA after radical prostatectomy.
The use of neoadjuvant androgen deprivation does reduce the incidence of positive margins, but to date has not been shown to affect disease-free survival.
Surgical measures to reduce postoperative complications including nerve sparing and bladder neck preservation do not appear to increase the incidence of positive margins if employed in appropriate cases.
It is inevitable that, with the inadequacies of current staging techniques, positive surgical margins will occur. It appears from retrospective data that adjuvant radiotherapy is of benefit, at least in terms of local disease control, to patients with positive margins in the absence of seminal vesicle or lymph node involvement. However, in men whose post-operative PSA becomes undetectable it is probably safe to watch and irradiate if the PSA starts to climb, provided the PSA is below 1.5 ng/ml. Large trials, currently underway in Europe and North America, are expected to shed more light on the role of androgen deprivation in patients with positive surgical margins.
